These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

360 related items for PubMed ID: 27283986

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Effects of the HDAC inhibitor CG2 in combination with irinotecan, 5-fluorouracil, or oxaliplatin on HCT116 colon cancer cells and xenografts.
    Na YS, Kim SM, Jung KA, Yang SJ, Hong YS, Ryu MH, Ro S, Cho DH, Kim JC, Jin DH, Lee JS, Kim TW.
    Oncol Rep; 2010 Dec; 24(6):1509-14. PubMed ID: 21042746
    [Abstract] [Full Text] [Related]

  • 3. HDAC2 deficiency and histone acetylation.
    Ree AH, Folkvord S, Flatmark K.
    Nat Genet; 2008 Jul; 40(7):812-3; author reply 813. PubMed ID: 18583969
    [No Abstract] [Full Text] [Related]

  • 4. MSH3 mismatch repair protein regulates sensitivity to cytotoxic drugs and a histone deacetylase inhibitor in human colon carcinoma cells.
    Park JM, Huang S, Tougeron D, Sinicrope FA.
    PLoS One; 2013 Jul; 8(5):e65369. PubMed ID: 23724141
    [Abstract] [Full Text] [Related]

  • 5. Molecular and biologic analysis of histone deacetylase inhibitors with diverse specificities.
    Newbold A, Matthews GM, Bots M, Cluse LA, Clarke CJ, Banks KM, Cullinane C, Bolden JE, Christiansen AJ, Dickins RA, Miccolo C, Chiocca S, Kral AM, Ozerova ND, Miller TA, Methot JL, Richon VM, Secrist JP, Minucci S, Johnstone RW.
    Mol Cancer Ther; 2013 Dec; 12(12):2709-21. PubMed ID: 24092806
    [Abstract] [Full Text] [Related]

  • 6. SB939, a novel potent and orally active histone deacetylase inhibitor with high tumor exposure and efficacy in mouse models of colorectal cancer.
    Novotny-Diermayr V, Sangthongpitag K, Hu CY, Wu X, Sausgruber N, Yeo P, Greicius G, Pettersson S, Liang AL, Loh YK, Bonday Z, Goh KC, Hentze H, Hart S, Wang H, Ethirajulu K, Wood JM.
    Mol Cancer Ther; 2010 Mar; 9(3):642-52. PubMed ID: 20197387
    [Abstract] [Full Text] [Related]

  • 7. Suberoylanilide hydroxamic acid enhances the antitumor activity of oxaliplatin by reversing the oxaliplatin‑induced Src activation in gastric cancer cells.
    Zhou C, Ji J, Shi M, Yang L, Yu Y, Liu B, Zhu Z, Zhang J.
    Mol Med Rep; 2014 Nov; 10(5):2729-35. PubMed ID: 25199623
    [Abstract] [Full Text] [Related]

  • 8. Modulation of thymidilate synthase and p53 expression by HDAC inhibitor vorinostat resulted in synergistic antitumor effect in combination with 5FU or raltitrexed.
    Di Gennaro E, Bruzzese F, Pepe S, Leone A, Delrio P, Subbarayan PR, Avallone A, Budillon A.
    Cancer Biol Ther; 2009 May; 8(9):782-91. PubMed ID: 19270508
    [Abstract] [Full Text] [Related]

  • 9. A novel histone deacetylase inhibitor exhibits antitumor activity via apoptosis induction, F-actin disruption and gene acetylation in lung cancer.
    Tang YA, Wen WL, Chang JW, Wei TT, Tan YH, Salunke S, Chen CT, Chen CS, Wang YC.
    PLoS One; 2010 Sep 14; 5(9):e12417. PubMed ID: 20856855
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. SAHA inhibits the growth of colon tumors by decreasing histone deacetylase and the expression of cyclin D1 and survivin.
    Jin JS, Tsao TY, Sun PC, Yu CP, Tzao C.
    Pathol Oncol Res; 2012 Jul 14; 18(3):713-20. PubMed ID: 22270866
    [Abstract] [Full Text] [Related]

  • 12. Preclinical activity of the rational combination of selumetinib (AZD6244) in combination with vorinostat in KRAS-mutant colorectal cancer models.
    Morelli MP, Tentler JJ, Kulikowski GN, Tan AC, Bradshaw-Pierce EL, Pitts TM, Brown AM, Nallapareddy S, Arcaroli JJ, Serkova NJ, Hidalgo M, Ciardiello F, Eckhardt SG.
    Clin Cancer Res; 2012 Feb 15; 18(4):1051-62. PubMed ID: 22173548
    [Abstract] [Full Text] [Related]

  • 13. MHY446 induces apoptosis via reactive oxygen species-mediated endoplasmic reticulum stress in HCT116 human colorectal cancer cells.
    Ahn YR, Jang JY, Kang YJ, Oh HJ, Kang MK, Yoon D, Kim HS, Moon HR, Chung HY, Kim ND.
    J Chemother; 2024 Oct 15; 36(6):483-500. PubMed ID: 38054850
    [Abstract] [Full Text] [Related]

  • 14. Lansoprazole as a potent HDAC2 inhibitor for treatment of colorectal cancer: An in-silico analysis and experimental validation.
    Khadempar S, Lotfi M, Haghiralsadat F, Saidijam M, Ghasemi N, Afshar S.
    Comput Biol Med; 2023 Nov 15; 166():107518. PubMed ID: 37806058
    [Abstract] [Full Text] [Related]

  • 15. Novel β-Carboline/Hydroxamic Acid Hybrids Targeting Both Histone Deacetylase and DNA Display High Anticancer Activity via Regulation of the p53 Signaling Pathway.
    Ling Y, Xu C, Luo L, Cao J, Feng J, Xue Y, Zhu Q, Ju C, Li F, Zhang Y, Zhang Y, Ling X.
    J Med Chem; 2015 Dec 10; 58(23):9214-27. PubMed ID: 26555243
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Suberoylanilide hydroxamic acid (SAHA) enhances olaparib activity by targeting homologous recombination DNA repair in ovarian cancer.
    Konstantinopoulos PA, Wilson AJ, Saskowski J, Wass E, Khabele D.
    Gynecol Oncol; 2014 Jun 10; 133(3):599-606. PubMed ID: 24631446
    [Abstract] [Full Text] [Related]

  • 19. Different Schedule-Dependent Effects of Epigenetic Modifiers on Cytotoxicity by Anticancer Drugs in Colorectal Cancer Cells.
    Hosokawa M, Tanaka S, Ueda K, Iwakawa S.
    Biol Pharm Bull; 2017 Dec 01; 40(12):2199-2204. PubMed ID: 28954936
    [Abstract] [Full Text] [Related]

  • 20. Troglitazone inhibits histone deacetylase activity in breast cancer cells.
    Davies GF, Ross AR, Arnason TG, Juurlink BH, Harkness TA.
    Cancer Lett; 2010 Feb 28; 288(2):236-50. PubMed ID: 19699029
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.